Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Mise à jour : Il y a 4 ans
Référence : NCT00431561

Femme et Homme

Extrait

In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade glioma.


Critère d'inclusion

  • Glioblastoma ,Anaplastic Astrocytoma


Liens